NovImmune garners $46M in second round
|
VENTURE CAPITAL |
|||
|
COMPANY |
AMOUNT/ROUND |
LEAD INVESTORS |
DESCRIPTION |
|
NovImmune
|
$46M
|
BZ Bank and Private Equity Investors |
NovImmune will use the funds to advance further products from its pipeline of fully human antibodies into clinical development. |
|
VaxInnate
|
$40M
|
Leaf Venture Partners and Canaan Partners |
VaxInnate is developing new flu vaccines. |
|
Esperance Pharmaceuticals
|
$9M
|
Themelios Ventures Partners and Research Corporation Technologies |
Esperance is developing a targeted anticancer fusion protein that is selectively toxic to cancer cells. |